Merck Provides Update on REVEAL Outcomes Study
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck remains blinded to the actual results of this analysis and to other REVEAL safety and efficacy data. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
CONCLUSION: Essential and dystonic vocal tremors responded differently to treatment. Dystonic vocal tremors responded significantly to treatment with botulinum toxin but not oral propranolol. Essential vocal tremors did not respond significantly to either treatment, perhaps due to the small number of patients, which is a limitation of this research.
CONCLUSION: Patients arrived very sick and displayed poor survival after deceased donor transplantation.
CONCLUSION: Except for the STOP-BANG questionnaire, subjective evaluation of sleepiness, sleep quality, perception of onset, and total sleep time are not important parameters for the diagnosis of obstructive sleep apnea, which reinforces the need for an active search for better management of these patients.
Supercomputer-enabled advances in science and engineering
Presents the table of contents for this issue of the publication.
Presents a listing of the editorial board, board of governors, current staff, committee members, and/or society editors for this issue of the publication.